Dubai - Cytek® Biosciences Inc., leading manufacturer and supplier of flow cytometry products and services, has appointed Dubai-headquartered Alliance Global (AGBL) as exclusive distributor in the Middle East, Africa, Central Asia, Pakistan, Bangladesh and Sri Lanka.
“Cytek continues to expand globally. As the leading biomedical tools provider in the Middle East, Africa and Asia, AGBL is our ideal strategic partner in the region,” emphasized Steve Ziganti, VP Worldwide Sales and Services at Cytek® Biosciences.
Cytek® provides compact, affordable instruments with high multiplexing capability to support medical researchers, scientists and clinicians. In addition, its five laser flow cytometer makes 40 colors possible – and to date, is the only commercialized fluorescence-based flow cytometry platform capable of doing so. The company is consolidating its position as the leading flow cytometry source for scientists in immunology, immuno-oncology, leukemia and lymphoma labs, cancer/stem cell research, and extra-cellular vesicle research.
“The addition spectral flow cytometry to our portfolio of innovative products is going to have a major positive impact on the way our customers run their flow cytometry assays, the partnership we have with Cytek is both strategic and key to our mission and growth and we look forward to a solid relationship with”, said Dr Nassim-Marie Hambouz, Group Commercial Director at AGBL.
About AGBL
Alliance Global Group of companies is the largest biomedical gateway in the Middle East, Africa, and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the region’s emerging healthcare market. The group's mission is to improve lives through novel biomedical technologies and products.
www.agbl.net
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.